Benzinga | Oct 5, 2020 08:32AM EDT

DURECT Corporation To Present Additional Safety And Efficacy Signals From Phase 1b Clinical Trial Of DUR-928 In NASH Patients At The Liver Meeting Digital Experience 2020 Nov. 13-16

CUERTINO, Calif., Oct. 5, 2020 /PRNewswire/ --DURECT Corporation (NASDAQ:DRRX) today announced it will present a poster at The AASLD Liver Meeting Digital Experience (tm) (TLMdX) 2020, to be held virtually on November 13-16, 2020.

Topline results from the 4-week Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patientswere released previously, showing an overall improvement from baseline in liver enzymes, liver stiffness, and serum lipid profiles. At day 28, 43% of patients showed ? 10% liver fat reduction from baseline as measured by magnetic resonanceimaging - proton density fat fraction(MRI-PDFF). Daily oral dosing of DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day). Additional safety and efficacy data will be presented in the poster.

Poster Presentation Details:

Title: Safety and Efficacy Signals of 4-Week Oral DUR-928 in NASH Subjects

Session: NAFLD and NASH: Therapeutics - Pharmacologic and Other

Presenter: Eric Lawitz, M.D., Vice President, Scientific and Research Development, Texas Liver Institute

The poster will be available for viewing by attendees of the LiverDate/Time: Meeting throughout the entire meeting and will transition to LiverLearning(R) after the meeting concludes